The incumbent provides strategic statistical leadership and collaborates with EDO stakeholders on clinical development plan strategy, study design including innovative statistical methods, endpoint design and selection, dose escalation, dosage optimization, cohort expansion, proof-of-concept assessment, and program advancement decisions. Provides strategic Biostatistics leadership and consultancy across the EDO portfolio, including biomarkers, innovative study design, dose escalation, dose and schedule optimization, cohort expansion, proof-of-concept assessment, and program advancement or transition decisions.